Toxicities From GPRC5D-Targeting Therapies in Multiple Myeloma

Data support prophylactic treatment with tocilizumab as an option to mitigate the risk of CRS for outpatient dosing of teclistamab.

Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.

Most infection events among those with newly diagnosed multiple myeloma in the MajesTEC-7 trial appeared to occur early during study treatment.

Experts discuss key data updates in real-world newly diagnosed multiple myeloma practices, and how these findings may change the treatment paradigm.

Similar outcomes were noted when linvoseltamab and teclistamab were analyzed as treatments for patients with relapsed/refractory multiple myeloma.

Data suggest that those with relapsed/refractory multiple myeloma and poor functional status may benefit from talquetamab without increased toxicity.